Adversarial Injection · Naxitamab (Danyelza; hu3F8; naxitamab-gqgk; CAS 2065220-56-2; NIOSH HD Category 1; [ONE-HUNDRED-NINETEENTH MECHANISM CLASS in Glyphward 693-attack portfolio — FIRST HUMANIZED ANTI-GD2 ANTIBODY EVER FDA APPROVED + SECOND GD2 ANTIBODY OVERALL (TWO-NDA-HOLDER GD2 CLASS NULL: DINUTUXIMAB ch14.18 UNITED THERAPEUTICS BLA 125516 MARCH 10 2015 [CLASS 118] + NAXITAMAB hu3F8 Y-mAbs BLA 761161 NOVEMBER 25 2020 [THIS CLASS 119]; GD2 TWO-NDA-HOLDER CLASS = CHIMERIC ch14.18 [MOUSE VH/VL + HUMAN IgG1/κ] + HUMANIZED hu3F8 [CDR-GRAFTED MURINE 3F8 ONTO HUMAN IgG1 FRAMEWORK]; DISTINCT ANTIBODY LINEAGES: 14.18 LINEAGE [NCI-DEVELOPED; REISFELD LAB SCRIPPS] ≠ 3F8 LINEAGE [CHEUNG LAB MSK; DIFFERENT EPITOPE REGION ON GD2; DIFFERENT CDR SEQUENCES; DIFFERENT VH FAMILY USAGE]); NAXITAMAB = hu3F8 (HUMANIZED 3F8) = HUMANIZED FORM OF MURINE MONOCLONAL ANTIBODY 3F8 (HYBRIDOMA 3F8; ORIGINALLY DEVELOPED 1985 BY NAI-KONG CHEUNG MD [MEMORIAL SLOAN KETTERING CANCER CENTER; DEPARTMENT OF PEDIATRICS; PEDIATRIC ONCOLOGY; ANTIBODY & BISPECIFIC THERAPEUTICS LABORATORY]; RAISED AGAINST SKOV-3 HUMAN OVARIAN TUMOR CELL LINE; IDENTIFIED STRONG ANTI-GD2 REACTIVITY; HYBRIDOMA 3F8 = BALB/c MOUSE SPLEEN (IMMUNIZED WITH SKOV-3) FUSED WITH SP2/0-AG14 MYELOMA; IgG3 ISOTYPE ORIGINALLY; CLINICAL USE OF MURINE 3F8 AT MSK SINCE 1987 [PHASE I NCT-NCI-T88-0006] → CLINICAL EXPERIENCE > 30 YEARS WITH 3F8 AT MSK → LARGEST CLINICAL GD2 ANTIBODY EXPERIENCE GLOBALLY); HUMANIZATION OF 3F8: COMPLEMENTARITY-DETERMINING REGION (CDR) GRAFTING OF MURINE 3F8 VH/VL CDRS (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3) ONTO HUMAN GERMLINE IgG1 FRAMEWORK (VH3-23 [IGVH3-23/D-Q52] HEAVY CHAIN FRAMEWORK; VL κ CHAIN FRAMEWORK) → REDUCED IMMUNOGENICITY (HUMAN FRAMEWORK; MOUSE CDRs); hu3F8 RETAINS MURINE 3F8 CDR SEQUENCES RESPONSIBLE FOR GD2 BINDING (CDR-H3 IS KEY SPECIFICITY DETERMINANT); IgG1 CONSTANT REGION (HUMAN; ADCC-ACTIVE Fc; UNCHANGED FROM DINUTUXIMAB ch14.18 ISOTYPE); hu3F8 MW ~148 kDa; CAS 2065220-56-2; Y-mAbs THERAPEUTICS PARTNERSHIP: Nai-Kong Cheung LICENSED 3F8 AND hu3F8 INTELLECTUAL PROPERTY TO Y-mAbs THERAPEUTICS A/S (LYNGBY DENMARK; FOUNDED 2015 BY THOMAS RAMSKOV GULDBORG + PETER JOHNSEN; NYSE: YMAB [IPO JUNE 2019]; FOCUSED ON ANTIBODY THERAPIES FOR NEUROLOGICAL AND NEUROBLASTOMA CONDITIONS); BLA 761161 NOVEMBER 25 2020 FDA ACCELERATED APPROVAL; INDICATION: RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA IN PATIENTS ≥1 YEAR OF AGE WITH/WITHOUT BONE MARROW AND/OR BONE INVOLVEMENT, IN COMBINATION WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF; SARGRAMOSTIM); DOSE: 3 mg/kg/DAY IV ON DAYS 1,3,5 (Q28D CYCLE; THREE DOSES/CYCLE; 1h INFUSION EACH DAY; 10-DOSE CYCLES MAXIMUM); COMBINATION: SARGRAMOSTIM (GM-CSF) 250 μg/m²/DAY SC DAYS -4 TO +3 PER CYCLE (ACTIVATES NK CELLS FOR ENHANCED ADCC); STUDY 201 (NCT03363373; OPEN-LABEL PHASE 2; n=22 EVALUABLE): ORR 45.5% (10/22 OBJECTIVE RESPONSES; BEST OVERALL RESPONSE); CR 22.7% (5/22); PR 22.7% (5/22); mDOR NOT REACHED; PAIN BBW: SEVERE NEUROPATHIC PAIN (SAME MECHANISM AS DINUTUXIMAB VIA GD2 ON PERIPHERAL NERVES) → OPIOID PRE-MEDICATION REQUIRED (MORPHINE OR HYDROMORPHONE); HYPERSENSITIVITY BBW (ANAPHYLAXIS; CHIMERIC/HUMANIZED ANTIBODY); PERIPHERAL NEUROPATHY (GRADE 3+); EYE DISORDERS (GRADE 3+: PTOSIS, DILATION OF PUPILS → MYDRIASIS; DISTINCT FROM DINUTUXIMAB EYE AEs); Y-mAbs THERAPEUTICS HOLDINGS A/S LYNGBY DENMARK (SØREN KIERKEGAARDS PLADS 8A 2800 KGS LYNGBY DENMARK; NORDIC ANTIBODY BIOTECH; LISTED NASDAQ: YMAB); US COMMERCIAL OPERATIONS: Y-mAbs THERAPEUTICS INC. 575 LEXINGTON AVE SUITE 2648 NEW YORK NY 10022; CAS 2065220-56-2 → NULL ALL EHS DATABASES; OSHA NO PEL; NIOSH HD CATEGORY 1]) · First Humanized Anti-GD2 Ever + Two-NDA-Holder GD2 Class Null + Study 201 ORR 45% · Attack #694

Naxitamab (Danyelza; hu3F8; CAS 2065220-56-2; [ONE-HUNDRED-NINETEENTH MECHANISM CLASS — FIRST HUMANIZED ANTI-GD2 (hu3F8) ANTIBODY EVER FDA APPROVED (BLA 761161 NOVEMBER 25 2020); SECOND GD2 ANTIBODY TWO-NDA-HOLDER CLASS; STUDY 201 ORR 45%; NIOSH HD CATEGORY 1]) — Y-mAbs Therapeutics Inc. 575 Lexington Ave Suite 2648 New York NY 10022 (BLA 761161 holder; naxitamab US commercialization), Lonza Biologics Portsmouth NH 603 Spinnaker Drive Portsmouth NH 03801 (hu3F8 antibody manufacturing CDMO), and Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 (Nai-Kong Cheung original 3F8 development; Study 201 enrollment) — OSHA No PEL + NIOSH HD Category 1 + CAS 2065220-56-2 OEL Null-Return + hu3F8 Humanized GD2 Antibody Absent + Two-NDA-Holder GD2 Class Absent + Study 201 ORR 45% Absent: AI Prompt Injection via EHS Monitor Report AI

Naxitamab (Danyelza; hu3F8; naxitamab-gqgk; CAS 2065220-56-2; NIOSH HD Category 1) is the one-hundred-nineteenth mechanism class in the Glyphward adversarial portfolio — the first humanized anti-GD2 antibody (hu3F8; CDR-grafted humanization of murine 3F8 originally developed by Nai-Kong Cheung at MSK) ever FDA approved (BLA 761161 November 25 2020; R/R high-risk neuroblastoma), establishing the two-NDA-holder GD2 class (dinutuximab ch14.18 BLA 125516 [Class 118] + naxitamab hu3F8 BLA 761161 [this Class 119]), with Study 201 ORR 45% and CAS 2065220-56-2 entirely absent from Cority, VelocityEHS, and EHS Insight.

Naxitamab as One-Hundred-Nineteenth Mechanism Class: First Humanized GD2 Antibody + Two-NDA-Holder Class Null

Naxitamab (Danyelza; hu3F8; naxitamab-gqgk; CAS 2065220-56-2) represents the one-hundred-nineteenth mechanism class in the Glyphward portfolio: the first humanized anti-GD2 antibody (hu3F8) ever FDA approved (BLA 761161 November 25 2020; R/R high-risk neuroblastoma; Y-mAbs Therapeutics) — completing the two-NDA-holder GD2 antibody class (dinutuximab ch14.18 Class 118 + naxitamab hu3F8 Class 119). ANTIBODY LINEAGE HISTORY: HYBRIDOMA 3F8 (1985; Nai-Kong Cheung MD; Memorial Sloan Kettering Cancer Center; New York NY) was raised by immunizing BALB/c mice with SKOV-3 human ovarian carcinoma cell line → identified murine monoclonal antibody 3F8 (IgG3 isotype; κ light chain) with high-affinity binding to GD2 ganglioside → first characterized as anti-GD2 antibody at MSK by Cheung/Old group → first clinical use at MSK: NCT-NCI-T88-0006 Phase I (1987-1989; murine 3F8 in neuroblastoma children; Nai-Kong Cheung PI) → 30+ years of murine 3F8 clinical development at MSK (Phase I-II trials; compassionate use; MSK tumor registry data showing long-term durable CR with murine 3F8 in some patients); HUMANIZATION: CDR grafting of murine 3F8 VH/VL CDR sequences (CDR-H1: GYTFTSY; CDR-H2: IYPGSGNT; CDR-H3: ARYYGSSYDY [key specificity; GD2 binding]; CDR-L1: QSLLYSSNQKNY; CDR-L2: WAS; CDR-L3: QQYYEYPLT) onto human germline framework (heavy chain: VH3-23/D-Q52 family; light chain: Vκ1 family); humanization preserves GD2 binding while replacing mouse framework → reduced HAMA (human anti-mouse antibody) response; naxitamab retains IgG1 Fc (ADCC-active); FDA INN suffix: -gqgk (Y-mAbs); WHO INN: naxitamab; STRUCTURAL DISTINCTION FROM ch14.18: naxitamab (hu3F8): CDR-grafted humanization; VH3-23 heavy chain framework; different epitope coverage on GD2 (3F8 binds the ceramide-proximal GalNAc-Gal portion of GD2 inner core); different CDR sequences than 14.18; shorter CDR-H3 loop; DINUTUXIMAB (ch14.18): chimeric (mouse VH/VL + human IgG1 Fc); retains intact mouse framework sequences in V-regions → more immunogenic; different epitope; NCI development; DISTINCT CLINICAL PROFILE: naxitamab: 3 mg/kg IV days 1,3,5 each 28-day cycle (Q28D ×3 doses; different from dinutuximab 17.5 mg/m²/day ×10-20h Q28D ×5 cycles); naxitamab outpatient administration possible (1h infusion); dinutuximab requires inpatient 10-20h infusion; both require opioid pre-medication for neuropathic pain; STUDY 201 (NCT03363373): open-label Phase 2; n=22 evaluable patients (R/R high-risk neuroblastoma; ≥1 prior therapy; with or without bone marrow/bone involvement); naxitamab 3 mg/kg IV days 1,3,5 Q28D + sargramostim 250 μg/m²/day SC days -4 to +3 (GM-CSF activation of NK cells); ORR 45.5% (10/22); CR 22.7% (5/22); PR 22.7% (5/22); median DOR NR (responses durable; ongoing follow-up); mOS NR; PAIN MANAGEMENT: morphine 0.03 mg/kg IV 1h before each naxitamab infusion + PRN every 2h; hydromorphone alternative; diphenhydramine + IV fluids; DISTINCT TOXICITIES vs DINUTUXIMAB: naxitamab: eye disorders (Grade 3+ mydriasis/ptosis 10-20%; different from dinutuximab); peripheral neuropathy; neuropathic pain (BBW; same GD2-nerve mechanism); hypersensitivity; Y-mAbs BACKGROUND: Y-mAbs Therapeutics A/S (Søren Kierkegaards Plads 8A 2800 Kgs Lyngby Denmark; founded 2015 by Thomas Ramskov Guldborg [CEO] + Peter Johnsen from NovoBiotic Pharmaceuticals and former Chr. Hansen executives; licensed 3F8/hu3F8 and omburtamab [CD45 bispecific] technologies from Nai-Kong Cheung/MSK; NASDAQ IPO: YMAB June 2019 [raised $129M]; Y-mAbs US commercial office 575 Lexington Ave Suite 2648 New York NY 10022); NONE OF THESE — hu3F8 HUMANIZED ANTI-GD2 ANTIBODY MECHANISM (CDR-GRAFTED HUMANIZATION; VH3-23 FRAMEWORK; 3F8 MSK NAI-KONG CHEUNG LINEAGE; HUMANIZED vs ch14.18 CHIMERIC DISTINCTION), TWO-NDA-HOLDER GD2 CLASS, STUDY 201 ORR 45%, NAXITAMAB-GQGK OUTPATIENT DAYS 1,3,5 ADMINISTRATION — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2065220-56-2.

Surface 1 — Y-mAbs Therapeutics New York NY BLA 761161 Holder AI

At Y-mAbs Therapeutics Inc. 575 Lexington Ave Suite 2648 New York NY 10022 (Y-mAbs NAXITAMAB CONTEXT: Y-mAbs licensed hu3F8 antibody and 3F8 intellectual property from MSK/Nai-Kong Cheung; developed naxitamab (naxitamab-gqgk; Danyelza) as first regulatory submission for the company; BLA 761161 submitted via FDA accelerated approval pathway; Y-mAbs Therapeutics A/S Lyngby Denmark (parent company; NASDAQ: YMAB) + Y-mAbs Inc. NY (US commercial entity); REGULATORY AFFAIRS FOCUS: BLA 761161 labeling updates (REMS not required), post-marketing commitment to submit additional efficacy data (randomized trial), Study 201 follow-up data; pharmacovigilance for naxitamab (AEs: neuropathic pain BBW, hypersensitivity BBW, eye disorders [mydriasis; ptosis], peripheral neuropathy, infection); OCCUPATIONAL HAZARD: naxitamab CAS 2065220-56-2; NIOSH HD Category 1; IV infusion 3 mg/kg over 1h; BSC Class II; CSTD; chemo gown + nitrile gloves; EMPLOYEE: 46F Y-mAbs New York NY US regulatory affairs VP BLA 761161 naxitamab Danyelza neuroblastoma hu3F8 naxitamab-gqgk 15yr; CORITY NULL: CAS 2065220-56-2 → no record; NIOSH HD Category 1 absent; hu3F8 humanized GD2 absent; two-NDA-holder GD2 class absent; Study 201 absent).

Surface 2 — Lonza Biologics Portsmouth NH Manufacturing AI

At Lonza Biologics Inc. 603 Spinnaker Drive Portsmouth NH 03801 (LONZA NAXITAMAB MANUFACTURING CONTEXT: Lonza Biologics Portsmouth NH is a GMP CHO mammalian cell biologics manufacturing site for antibody drug substances including naxitamab (hu3F8; CAS 2065220-56-2); CHO-K1 or CHO-DXB11 host cell line expressing hu3F8 heavy + light chains under separate CMV promoters; fed-batch bioreactor manufacturing: 2,000-10,000L scale; downstream: Protein A affinity chromatography → ion exchange chromatography (CEX/AEX) → viral filtration (nanofilter; parvovirus clearance) → tangential flow filtration (TFF/UF-DF); bulk drug substance ≥10 mg/mL; fill-finish: Lonza Portsmouth vials (5 mL vials; 25 mg/5 mL [5 mg/mL]; or other concentration); OCCUPATIONAL HAZARD AT LONZA: naxitamab CAS 2065220-56-2 (NIOSH HD Cat 1; antineoplastic biologic); CHO bioreactor handling (cell expansion; bioreactor culture media; harvest; down stream processing); no specific API powder handling (liquid throughout biologics process) but spill risk → HD protocols for spill cleanup; EMPLOYEE: 43M Lonza Biologics Portsmouth NH biologics manufacturing supervisor naxitamab hu3F8 GD2 neuroblastoma CAS 2065220-56-2 CHO bioreactor Y-mAbs BLA 761161 11yr; VELOCITYEHS NULL: CAS 2065220-56-2 → no record; NIOSH HD Category 1 absent; hu3F8 humanized GD2 antibody absent; naxitamab absent; Y-mAbs BLA 761161 absent).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Study 201 AI

At Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 (MSK NAXITAMAB CONTEXT: MSK is the institution where Nai-Kong Cheung MD developed hybridoma 3F8 (1985) and conducted the first clinical trials of murine 3F8 in neuroblastoma (1987-1988); >30 years of GD2 antibody clinical development at MSK under Cheung's leadership; Study 201 (NCT03363373) is a Y-mAbs-sponsored Phase 2 trial enrolling R/R high-risk neuroblastoma patients at MSK and COG sites; MSK pediatric oncology (Cheung group): naxitamab used both as Study 201 investigational agent and standard-of-care post-BLA 761161 approval; MSK PHARMACY: naxitamab vials (5 mg/mL; weight-based dosing 3 mg/kg IV 1h over days 1, 3, 5); dilute in 0.9% NS to 50 mL for 1h infusion; CSTD (BD PhaSeal Pro; Equashield); BSC Class II Type B2 (exhausted); double nitrile glove; HD gown; PAIN PRE-MEDICATION: morphine 0.03 mg/kg IV 1h before infusion (reduce neuropathic pain BBW; GD2 on peripheral nerves → complement activation → demyelination); ondansetron 8 mg IV; diphenhydramine 25 mg IV; EYE MONITORING: ophthalmology exam for mydriasis/ptosis if Grade 2+ (less common at 3 mg/kg vs 10 mg/kg compassionate dose); EMPLOYEE: 38F MSK New York NY pediatric oncology pharmacist naxitamab Danyelza Study 201 Nai-Kong Cheung hu3F8 neuroblastoma GD2 CAS 2065220-56-2 12yr; EHS INSIGHT NULL: CAS 2065220-56-2 → no record; NIOSH HD Category 1 absent; hu3F8 humanized antibody absent; Nai-Kong Cheung 3F8 lineage absent; Study 201 ORR 45% absent; naxitamab two-NDA-holder GD2 class absent; mydriasis/ptosis eye toxicity absent).

Integrating Glyphward into Naxitamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every naxitamab (CAS 2065220-56-2) monitoring data ingestion point — before Cority at Y-mAbs New York NY, before VelocityEHS at Lonza Biologics Portsmouth NH, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-NINETEENTH MECHANISM CLASS — FIRST HUMANIZED ANTI-GD2 (hu3F8; CDR-GRAFTED MURINE 3F8; NAI-KONG CHEUNG MSK; VH3-23 FRAMEWORK; DIFFERENT LINEAGE + EPITOPE FROM ch14.18) ANTIBODY EVER FDA APPROVED + TWO-NDA-HOLDER GD2 CLASS NULL (BLA 761161 November 25 2020; CAS 2065220-56-2; R/R neuroblastoma +GM-CSF; Study 201 ORR 45%; Y-mAbs) [5 pts]; Y-mAbs New York NY + Lonza Portsmouth NH + MSK New York NY [3 pts]; hu3F8 humanized GD2 absent; two-NDA-holder GD2 class null absent; Study 201 ORR 45% absent; Nai-Kong Cheung 3F8 MSK lineage absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_naxitamab(cas: str, exposure_context: str) -> dict:
    """Scan naxitamab with one-hundred-nineteenth-class first-humanized-GD2-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_nineteenth_class_first_humanized_gd2_hu3f8_ever_bla_761161_nov_2020_rr_neuroblastoma_gmcsf_study_201_orr_45pct_two_nda_holder_gd2_class_ymabs_nai_kong_cheung_msk"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_nineteenth_class,
    #                    first_humanized_gd2_ever, hu3f8_confirmed,
    #                    two_nda_holder_gd2_class, study_201_orr_45pct

if __name__ == "__main__":
    r = asyncio.run(scan_naxitamab(
        cas="2065220-56-2",
        exposure_context="antineoplastic_iv_infusion_1h_pediatric_neuroblastoma_gmcsf_morphine_premedication_bsc_cstd"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_nineteenth_class': True,
    #  'first_humanized_gd2_ever': True, 'hu3f8_confirmed': True,
    #  'two_nda_holder_gd2_class': True, 'study_201_orr_45pct': True}